Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Serotonin Syndrome × lanreotide × Clear all

Phase

Status

Sponsor Class

NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 5 Carcinoid Tumor 2 Serotonin Syndrome 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Intestinal Obstruction 1 Gastro-enteropancreatic neuroendocrine tumor 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma 1 Adenoma, Islet Cell 1

Interventions

telotristat ethyl 1 pasireotide 1 lanreotide 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Random Allocation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed

115 enrolled 17 charts

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡